Estrogen receptor-a (ERa, ESR1) is a pivotal transcriptional regulator of breast cancer physiology and is targeted by endocrine therapies. Loss of ERa activity or expression is an indication of endocrine resistance and is associated with increased risk of tumor recurrence and worse prognosis. In this study, we sought to investigate whether elements of the tumor microenvironment, namely macrophages, would impact on ERa and we found that macrophage-derived factors caused loss of ERa expression in breast cancer cells. Conditioned media from macrophages caused activation of several intracellular pathways in breast cancer cells of which c-Src, protein kinase c and mitogen-activated protein kinase (MAPK) were essential for loss of ERa expression. Moreover, a prolonged hyperactivation of MAPK was observed. The activation of this kinase cascade resulted in recruitment of extracellular signal regulated kinase 2 (ERK2) directly to chromatin at the ESR1 gene locus in a process that was dependent upon activation and recruitment of the c-Jun transcription factor. Thus, we identify a novel mechanism for loss of ERa expression in breast cancer cells via macrophage activation of kinase cascades in the cancer cells causing transcriptional repression of the ESR1 gene by a direct chromatin action of a c-Jun/ERK2 complex. The findings in this study support an alternative mechanism, not intrinsic to the tumor cell but derived from the crosstalk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ERa expression in breast tumors.
Introduction
Breast cancer is the second leading cause of death among the US women and is a major cause of morbidity and death worldwide (Jemal et al., 2009) . One of the most important prognostic factor and therapeutic target in breast cancer is the estrogen receptor-a (ERa), a member of the nuclear receptor superfamily of liganddependent transcription factors. ERa-positive breast tumors, which comprise circa 70% of primary breast cancers, have better prognosis and are targeted by endocrine therapies such as selective estrogen receptor modulators (for example, tamoxifen, raloxifene), aromatase inhibitors (for example, letrozole) and selective estrogen receptor down-regulators (for example, fulvestrant), which have been designed to oppose estrogen receptor action (Jordan and O'Malley, 2007; Musgrove and Sutherland, 2009 ).
However, the most aggressive breast tumors, for which effective treatments are lacking, tend to be resistant to endocrine therapies and are generally ERa negative. This group of malignancies represents ca. 30% of the total number of breast cancer cases. Moreover, up to half of ERa-positive primary tumors lose ERa expression in case of recurrence and ca. 30% of metastatic tumors that initially respond to tamoxifen therapy develop resistance by losing ERa expression (Johnston et al., 1995; Cheung et al., 1997; Johnston, 1997) . Apart from ERa-negativerelated mechanisms, several additional factors have been shown to cause endocrine resistance including deregulation of transcription factors and tyrosine kinase receptors, and alterations of intracellular signaling pathways (Brinkman and El-Ashry, 2009; Musgrove and Sutherland, 2009 ). For these reasons, understanding the mechanisms that cause loss of ERa expression is of paramount importance, whereas the development of novel strategies to prevent receptor loss or restore its level and activity are of therapeutic potential.
Macrophages are functionally dynamic elements of the immune system that are present in the tumor microenvironment and have been correlated with breast cancer progression, ER status and prognosis (Leek et al., 1996 (Leek et al., , 1999 Pupa et al., 1996; Shabo et al., 2008; Beck et al., 2009; Sharma et al., 2009) . Their functional profile is highly susceptible to dynamic changes in response to environmental cues (Lewis and Pollard, 2006; Watkins et al., 2007; Benoit et al., 2008; Martinez et al., 2008; Sica et al., 2008b) and it ranges from the M1 (pro-inflammatory) to the M2 (anti-inflammatory) states that can be elicited by lipopolysaccharides and/or interferon g or interleukin (IL)-4 and IL-13, respectively (Mantovani et al., 2002 (Mantovani et al., , 2004 Martinez et al., 2006; Sica et al., 2006 Sica et al., , 2008a Sica et al., , 2008b Yuan et al., 2008; Allavena et al., 2008a Allavena et al., , 2008b Qian and Pollard, 2010) . The macrophage population that is present at the tumor site is usually referred to as tumor-associated macrophages and mostly has M2-like properties (Sica et al., 2006 Allavena et al., 2008a; Movahedi et al., 2010) . Tumor-associated macrophages have been shown to promote tumor growth, invasion and metastasis in some types of cancer, whereas showing anti-tumor activities in others (Chen et al., 2005; Lewis and Pollard, 2006; Ohri et al., 2009; Ma et al., 2010; Redente et al., 2010) .
In this study, we investigated whether macrophages and their polarization (that is, M1 vs M2) would impact estrogen receptor activity in breast cancer cells. For this purpose, we generated and characterized an in vitro model of macrophage polarization using the monocytic THP-1 cell line and have found that conditioned media (CM) from differentiated and polarized THP-1 cells caused loss of ERa expression in MCF-7 breast cancer cells. We then analyzed in detail the molecular mechanisms underlying this phenomenon and found that the macrophage-elicited ERa downregulation was dependent on activation of the c-Src, mitogen-activated protein kinase (MAPK) and protein kinase c (PKC) pathways, which lead to recruitment of extracellular signal regulated kinase 2 (ERK2) and c-Jun to the ESR1 genomic locus. Thus, we demonstrate a previously unknown cross-talk between macrophages and breast cancer cells involving macrophage activation of kinase cascades in the breast cancer cells that leads to loss of ERa via a direct transcriptional repression mechanism involving the recruitment to chromatin of ERK2 and cJun. These findings support an alternative mechanism, not intrinsic to the tumor cell but derived from the cross-talk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ERa expression in breast tumors.
Results

THP-1 monocytic cells can be polarized into M1 vs M2-like macrophage phenotypes
To study the cross-talk between macrophages and breast cancer cells, we generated and characterized a human macrophage-like model that is easy to manipulate and that recapitulates the macrophage phenotypes ranging from the M1 pro-inflammatory to the M2 antiinflammatory. We chose for this study the monocytic (abbreviated 'Mn' in Figure 1a ) human THP-1 cell line, Macrophage-elicited loss of ERa in breast cancer cells F Stossi et al which was shown, upon differentiation, to have characteristics similar to human macrophages (Tsuchiya et al., 1982; Auwerx, 1991; Daigneault et al., 2010) . We then adapted a differentiation and polarization protocol ( Figure 1a ) that was shown to be effective for primary human macrophages (Martinez et al., 2006) . THP-1 cells were differentiated with the phorbol ester phorbol-12-myristate-13-acetate for 24 h followed by a resting period of 6 days at the end of which fully differentiated macrophages were generated (denoted as 'M0' in Figure 1 ). At this stage, differentiated THP-1 cells were treated with either interferon g or IL-4 for 24 h to obtain M1-and M2-like phenotypes, respectively (denoted as 'M1' and 'M2', Figure 1 ). To validate that this protocol was efficient in eliciting M1 and M2-like polarization in the THP-1 cells, we measured, by quantitative (q)-PCR, the expression level of selected genes that have been shown to discriminate between M1 and M2 in primary human macrophages (Martinez et al., 2006) , and we found that the THP-1 cell system was comparable as shown by data represented as the M1/M2 ratio ( Figure 1b ) and by expression of representative stimulus-specific genes ( Figure 1c ). Thus, these data demonstrate that, based on gene expression profiles, we were able to generate M1 and M2 polarized macrophage-like populations that we could utilize in studying the cross-talk with breast cancer cells.
CM from polarized THP-1 cells causes downregulation of ERa
To analyze the cross-talk between estrogen receptor signaling in breast cancer cells and polarized macrophages, we first examined ERa mRNA and protein expression by q-PCR and western blot, respectively, in MCF-7 breast cancer cells. Starting after 8 h of treatment with CM from polarized macrophages (for example, M1-like, interferon g treated (CM1)), we observed downregulation of ERa (Figures 2a and b) . We also found that loss of ERa was occurring after treatment with CM from both resting macrophages (CM0) and polarized ones (M1-like (CM1) or M2-like (CM2)), but that the M1-like (CM1) showed more profound and sustained effects over time, as observed in mRNA and protein time-course experiments (Figures 2a and b) .
We also checked if ERa downregulation was because of direct action of the cytokines used to polarize THP-1 cells (for example, IL-4 or interferon g) and we found this not to be the case (Figure 2a ). Moreover, we examined whether the effect of CM1 was because of transcriptional repression by monitoring RNA polymerase II levels at the ERa gene (ESR1) promoter A, which has been shown previously to be the most active of the characterized ESR1 promoters in MCF-7 cells (Kos et al., 2001) . As shown in Figure 2c , treatment of MCF-7 cells for 45 min with CM1 caused RNA polymerase II dismissal from the ESR1 promoter A, indicating that the reduction of ERa mRNA is primarily because of transcriptional repression.
Activation of MAPK, c-Src and PKC is required for macrophage-mediated downregulation of ERa in breast cancer cells
We next investigated which intracellular pathways might be activated by THP-1 CM1 and which ones would be necessary for downregulating ERa expression. To do this, we utilized a combined approach with small molecule pathway inhibitors and phospho-specific antibodies to probe selected intracellular pathways (for example, MAPK, PKC). After 15 min of treatment, CM from M1-like THP-1 cells (CM1) caused phosphorylation of several kinases, including c-Src, MAPK, p38MAPK, p90RSK, stress-activated protein kinase/ c-Jun NH 2 -terminal kinase, PKC, Akt and GSK3b ( Figure 3a ). To elucidate which of these pathways were essential for ERa mRNA downregulation, we pretreated MCF-7 cells with small molecule inhibitors followed by treatment with CM1. In examining the effect of the small molecule pathway inhibitors on ERa mRNA, we found that the c-Src (PP2), MEK1 (U0126) and PKC (Go¨6976) inhibitors were all able to prevent the CM1-mediated reduction of ERa mRNA ( Figure 3b ). This was observed also at the protein level as shown by western blot after 24-h treatment with the MAPK To understand the hierarchical activation of intracellular pathways by THP-1 CM, we combined small molecule inhibitors with activation of the pathways by using phospho-specific antibodies. After 15 min of treatment, the c-Src inhibitor PP2 was able to prevent activation of all the pathways involved in ERa downregulation, demonstrating c-Src to be the most upstream kinase, which then regulates the activation of two parallel downstream pathways (PKC and MAPK) (Figures 3d and e) .
Because one of the most downstream kinases activated by the CM was the MAPK and its constitutive activation has been shown to be involved in generation of ERa-negative tumors (Oh et al., 2001; Creighton et al., 2006; Bayliss et al., 2007) , we wanted to verify if its activation would be transient or sustained. As shown in Figure 3f , time-course analysis evidenced a strong and sustained phosphorylation of MAPK up to 48 h of treatment with CM1. These observations regarding the activation of c-Src and MAPK by macrophage-derived factors may be very relevant to breast cancer biology because hyperactivation of both pathways has been linked to loss of ERa in primary breast tumors and breast cancer cell lines (Creighton et al., 2006; Bayliss et al., 2007; Chu et al., 2007) .
ERK2 is recruited to the ESR1 genomic locus and is required for loss of ERa expression Our next step was to ask which transcription factors and coregulators might be involved in the transcriptional repression of ERa. Because of the strong and persistent activation of MAPK we observed upon exposure to THP-1 CM and based on our identification of genomewide ERK2-binding sites via chromatin immunoprecipitation (ChIP)-chip technology (Madak-Erdogan et al., 2011), we were able to identify five putative ERK2 interacting regions in the ESR1 genomic locus (Figure 4a ). We first verified by conventional ChIP assay if these regions would recruit ERK2 upon treatment of MCF-7 cells for 45 min with CM1. We detected an increase in ERK2 recruitment at three of the five putative ERK2-binding sites (sites 245, 246 and 248, Figure 4b ). To confirm the role of ERK2 in ERa downregulation, we performed RNAi experiments to reduce endogenous ERK2 levels. In Figure 4c , we transfected MCF-7 cells for 72 h with ERK2 or GL3 control siRNAs and then treated the cells with CM from THP-1 cells for 8 h (mRNA) or 24 h (protein) and observed an almost complete recovery of ERa mRNA and protein, confirming the central role of ERK2 in the loss of ERa (Figure 4c ). The knock-down efficiency of ERK2 siRNA was ca. 80% as measured by both mRNA and protein (Figure 4c ).
The transcription factor c-Jun is activated and recruited to the ESR1 genomic locus where it has a key role in the loss of ERa expression To find candidate transcription factors that the kinase ERK2 might be using to tether to chromatin, we performed bioinformatics analysis of the ERK2-binding sites at the ESR1 locus using available internet programs (for example, JASPAR from Karolinska Inst, Huddinge, Sweden; Match from BIOBASE, Wolfenbu¨ttel, Germany; PhastCons from University of California, Santa Cruz, CA, USA). Among the transcription factors whose motif was present in the ERK2-binding sites, we focused on cJun, a central part of the AP-1 transcription factor, because its over-expression in MCF-7 cells has been shown to lead to loss of ERa expression and its activity is elevated in tamoxifen-resistant tumors (Dumont et al., 1996; Johnston et al., 1999; Smith et al., 1999) . To examine the role of c-Jun in the loss of ERa expression, we first monitored if c-Jun was being activated by treatment with THP-1 CM. As shown in Figure 5a , c-Jun was activated by CM1, detected as an increase in phosphorylation of serine 73, in a biphasic and prolonged manner with a first peak at 15 min and then a second more prolonged peak after 1 h of treatment. Interestingly, we were also able to prevent c-Jun phosphorylation at serine 73 by pre-treating MCF-7 cells with the MAPK, c-Src and PKC inhibitors that also blocked ERa downregulation ( Figure 5b ). We then wanted to check if c-Jun was present and/or recruited to the ERK2-binding sites at the ESR1 locus upon treatment with CM1. By ChIP analysis, we observed that c-Jun was recruited uniquely at the ERK2_246 site while being detected (but not affected by treatment) at three other ERK2-binding sites (Figure 5c ). To further confirm the importance of c-Jun in regulating ERa expression, we performed c-Jun knock-down in MCF-7 cells. After 72 h of siRNA and 8 h (mRNA) or 24 h (protein) treatment with CM, we were able to prevent much of the loss of ERa mRNA and protein despite only a ca. 50% knock-down efficiency, suggesting a central role for c-Jun in ERa downregulation (Figure 5d ).
The transcription factor c-Jun is required for ERK2 recruitment to the ESR1 locus To determine whether c-Jun was indeed the main factor affecting ERK2 recruitment at the ESR1 locus, we first performed ChIP-reChIP analysis, which showed that ERK2 and c-Jun were present on chromatin in the Macrophage-elicited loss of ERa in breast cancer cells F Stossi et al same complex exclusively at the ERK2_246-binding site (Figure 6a ). Second, we transfected MCF-7 cells with control GL3 or c-Jun siRNA and then performed ChIP assays using an ERK2-specific antibody. As shown in Figure 6b , reduction of c-Jun levels resulted in the inability of ERK2 to be recruited to chromatin, indicating that c-Jun is an important transcription factor involved in the recruitment of ERK2 to the ESR1 locus.
Discussion
The ERa is a master regulator of breast cancer physiology, critically defining differences in the gene expression programs and the phenotypic properties of ERa-positive vs ERa-negative breast cancers and, as such, ERa is also the main therapeutic target in ca. 70% of breast cancer patients. Unfortunately, the most aggressive and poor prognostic tumors either lack expression of ERa or have become resistant to endocrine therapies. Understanding the mechanisms underlying the loss of ERa expression and the development of endocrine resistance should enable promising avenues in the search for novel therapeutic approaches to treat these aggressive breast tumors for which efficient therapies are currently lacking. The role of the tumor microenvironment as a causative effector of endocrine resistance has been largely understudied. In keeping with our findings here, studies in prostate cancer have shown important crosstalk between macrophages and tumor cells. In prostate cancer, this cross-talk was able to switch the action of selective androgen receptor modulators) from antagonists to agonists of the androgen receptor, indicating that the tumor microenvironment can greatly impact on the nature of therapeutic drugs by altering the status of activation of intracellular pathways (Zhu et al., 2006) .
Macrophages are central elements of the tumor microenvironment as they can form up to 50% of the tumor mass. Interest in TAMs stems from the fact that they are very dynamic cells that can have functions ranging from pro-inflammatory (M1-like population) to anti-inflammatory (M2-like population) depending largely on the nature of the microenvironmental cues ( Mantovani et al., 2002; Sica et al., 2006 Sica et al., , 2008b Martinez et al., 2008; Allavena et al., 2008a) . Moreover, they have been shown to be very attractive targets for immunotherapy and also drug delivery strategies. In this study, we generated and characterized an easily manipulable in vitro system that would allow us to study the cross-talk between sub-populations of polarized macrophages and breast cancer cells. Using THP-1 cells (a human monocytic cell line) and a protocol we devised for their differentiation and polarization into M1-and M2-like populations (Figure 1a) , and through the use of CM from polarized macrophagelike populations, we found that soluble factors secreted from THP-1 cells elicited loss of ERa expression in breast cancer cells. The discovery and characterization of such factors and receptors through detailed proteomic analysis will be undertaken in future work. In this study, as depicted in the model in Figure 6c , we have Macrophage-elicited loss of ERa in breast cancer cells F Stossi et al uncovered a new mechanism for transcriptional repression of the ESR1 gene, which occurs through hierarchical activation of multiple kinases (that is, c-Src, PKC and MAPK) that results in recruitment to chromatin of an ERK2 and c-Jun-containing complex that appears to be responsible for the loss of ERa expression. The mechanism described in this study fits very well with data from primary breast tumors where hyperactivation of MAPK and c-Src, and high content of TAMs are inversely correlated with ERa expression (Leek et al., 1996; Oh et al., 2001; Creighton et al., 2006; Chu et al., 2007) . In keeping with the importance of ERK2 activation also in our system, we found that ERK2 was not recruited to the ESR1 genomic locus when the MEK1 inhibitor U0126, which blocks ERK2 activation, was used (data not shown).
Moreover, we have established for the first time a direct action of activated ERK2 at the ESR1 genomic locus where this kinase works at the chromatin level, tethered by the AP-1 transcription factor, to actively contribute to transcriptional repression of the ESR1 gene. Recently, we reported on an extensive genomewide collaboration between ERa and ERK2 at the chromatin level that is important for estrogen regulation of gene expression and proliferation of breast cancer cells (Madak-Erdogan et al., 2011) . These findings are in keeping with other cell systems where nuclear MAPK has been shown to contribute to both transcriptional stimulation and repression, depending on the environmental cues (Lawrence et al., 2009) .
Thus, we demonstrate a previously unknown crosstalk between macrophages and breast cancer cells involving macrophage activation of kinase cascades in the breast cancer cells that leads to loss of ERa via a direct transcriptional repression mechanism involving the recruitment to chromatin of ERK2 and c-Jun. These findings support an alternative mechanism, not intrinsic to the tumor cell but derived from the cross-talk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ERa expression in breast tumors.
Materials and methods
Cell culture, treatments, RNA extraction and real-time qPCR MCF-7 and THP-1 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (Sigma Chemical Co., St Louis, MO, USA) supplemented with 10% heat-inactivated calf serum (Hyclone, Logan, UT, USA) and 1% antibiotics and Roswell Park Memorial Institute medium supplemented with 10% heat-inactivated foetal bovine serum, 1% antibiotics, sodium bicarbonate and b-mercaptoethanol, respectively. Before experiments, the cells were cultured in phenol red-free Dulbecco's modified Eagle's medium containing 10% charcoal stripped calf serum. THP-1 monocytic cells were differentiated with phorbol-12-myristate-13-acetate (PMA; 100 ng/ml, EMDCalbiochem, La Jolla, CA, USA) for 24 h, with media changed the next day and then every 2 days for 6 days before polarization. Polarization of these resting differentiated macrophages ('M0' cells) was performed as in (Martinez et al., 2006) using 20 ng/ml of interferon g (R&D Systems, Minneapolis, MN, USA) for M1 polarization or 30 ng/ml of IL-4 (R&D Systems) for M2 polarization. CM from differentially polarized THP-1 cells was harvested after 24 h and centrifuged for 10 min at maximum speed before addition to MCF-7 cells or was frozen at À80 1C (Figure 1a) .
For pathway inhibitor experiments, MCF-7 cells were pretreated with inhibitors for 1 h before addition of CM. The inhibitors used were purchased from EMD-Calbiochem (MEK1 inhibitor (U0126, 20 mM) ), c-Src inhibitor (PP2, 1 mM), PKC inhibitor (Go¨6976, 1 mM), p38MAPK inhibitor (SB203580, 10 mM), mitogen-activated protein kinase/signal transducer and activator of transcription inhibitor (pan mitogen-activated protein kinase inhibitor, 5 mM); Sigma (nuclear factor-kB inhibitor, (parthenolide, 10 mM)), and Cayman Chemical, Ann Arbor, MI, USA (c-Jun NH2-terminal kinase inhibitor (SP600125, 10 mM)).
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Quantitative real-time-PCR (q-PCR) was performed as described previously (Stossi et al., 2004) . All PCR primer sequences are available upon request.
ChIP and reChIP assays
ChIP assays were performed as described (Metivier et al., 2003) . The antibodies used were from Santa Cruz Biotechnology, Santa Cruz, CA, USA (ERK2 (D-2), c-Jun (H-79), RNA polymerase II (N-20) ). ChIP/reChIP experiments were performed as in (Stossi et al., 2009) . After the first pull-down, immunoprecipitated material was recovered with 10 mM dithiothreitol in immunoprecipitation buffer at 37 1C for 30 min, diluted and submitted to a second round of immunoprecipitation.
RNA interference and western immunoblotting MCF-7 cells were transfected with c-Jun or ERK2 SMARTpool or GL3 luciferase control siRNAs (Dharmacon, Lafayette, CO, USA) following the manufacturer's instructions. After 72 h, cells were treated with THP-1 CM for 8 or 24 h. Total RNA was harvested, prepared and analyzed as described in the previous section.
Western immunoblotting were performed on whole cell extracts following standard protocols. The antibodies used were purchased from Santa Cruz Biotechnology (ERa (F-10), ERK2 (D-2), c-Jun (H-79)), Cell Signaling Technology, Danvers, MA, USA (PathScan Multiplex Western Blot Cocktails I, II, III; Src antibody sampler kit, phospho-PKC sampler kit, phospho Akt pathway antibody sampler kit, phospho-c-Jun (ser 73). Imaging and quantitation of the western blots used an Odyssey instrument (LI-COR Biosciences, Lincoln, NE, USA) following the manufacturer's instructions.
Abbreviations ER, estrogen receptor; E2, 17b-estradiol; IFNG, interferon g; IL-4, interleukin 4; PMA, phorbol-12-myristate-13-acetate; CM, conditioned media; TAMs, tumor-associated macrophages.
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